Skip to content
value.today

Prosetta Biosciences Inc.

Total raised
$31 M
1 round on record
Latest round
$31 M
Feb 2015
First round on record
Feb 2015
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Prosetta Biosciences Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2015$31 MNo. 1$10 to $50 million

Prosetta Biosciences Inc.: Raise no. 1, Feb 2015

Investors in this round

23 investors had bought by the notice of Dec 4, 2015: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$31 M of $31 M offered
Smallest investment taken
$6,750
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,114,407
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael D. Farmer · Executive Officer, Director
  • Vishwanath D. Lingappa · Executive Officer, Director
  • "Joseph(""Mike"")" D. McCune · Director
  • Abel D. Weinrib · Director
  • CJ D. Sylvester · Director
  • David D. Keys · Director
  • Karl D. Manheim · Director
  • Molly D. Coye · Director
  • Phil D. Satow · Director
  • Thomas D. Higgins · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • T.R. Winston & Company, LLC (CRD 10571) · Los Angeles, CaliforniaSold in CA, MA, MI, NY, OR, PA, WA

Remarks in the notice

  • On fees: “T.R.Winston will also receive warrants to purchase Series D Preferred Stock with an aggregate value equal to 3.0% of gross proceeds raised in the offering and reimbursement for legal expenses up to $50,000.”

Signed by Michael D. Farmer, President & Co-CEO. Source: SEC Form D, newest notice filed Dec 4, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Prosetta Biosciences Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2015).

    SEC Form D · Dec 2015

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2015

That is all the official record says: Prosetta Biosciences Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Prosetta Biosciences Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 23 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Prosetta Biosciences Inc.
NameRoleNamed in
Michael D. FarmerExecutive officerDec 2015
Vishwanath D. LingappaExecutive officerDec 2015
"Joseph(""Mike"")" D. McCuneDirectorDec 2015
Abel D. WeinribDirectorDec 2015
CJ D. SylvesterDirectorDec 2015
David D. KeysDirectorDec 2015
Karl D. ManheimDirectorDec 2015
Michael D. FarmerDirectorDec 2015
Molly D. CoyeDirectorDec 2015
Phil D. SatowDirectorDec 2015
Thomas D. HigginsDirectorDec 2015
Vishwanath D. LingappaDirectorDec 2015